Corvus Pharmaceuticals CRVS
$9.67 −$0.34 (-3.40%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.67 0.00%
Open$9.84
Prev close$10.01
Day range$9.56 – $10.04
Volume927.5K
Market cap$815.69M
P/E (TTM)–
Dividend yield–
Analyst view
ConsensusBuy
Analysts3
Average target$27.33+182.6% vs. price
- Buy 100%
Low $27.00Now $9.67Avg $27.33High $28.00
Recent rating changes
The last 20 actions on file set price targets from $27.00 to $40.00, averaging $30.25.
| Date | Firm | Rating | Target |
|---|---|---|---|
| 11 Nov 2026 | H.C. Wainwright | BUY | $27.00 |
| 6 Nov 2026 | Barclays | BUY | $28.00 |
| 29 Oct 2026 | Mizuho Securities | BUY | $27.00 |
| 11 Aug 2026 | Mizuho Securities | BUY | $30.00 |
| 10 Aug 2026 | H.C. Wainwright | BUY | $27.00 |
| 7 Aug 2026 | Barclays | BUY | $28.00 |
| 7 Aug 2026 | Oppenheimer | BUY | $33.00 |
| 1 Jul 2026 | H.C. Wainwright | BUY | $27.00 |
| 12 Jun 2026 | Mizuho Securities | BUY | $30.00 |
| 18 May 2026 | Mizuho Securities | BUY | $30.00 |
| 15 May 2026 | H.C. Wainwright | BUY | $27.00 |
| 15 May 2026 | Barclays | BUY | $28.00 |
| 14 May 2026 | Goldman Sachs | BUY | $40.00 |
| 11 May 2026 | Mizuho Securities | BUY | $30.00 |
| 11 May 2026 | Goldman Sachs | BUY | $40.00 |
| 8 May 2026 | Barclays | BUY | $28.00 |
| 17 Apr 2026 | Goldman Sachs | BUY | $40.00 |
| 16 Mar 2026 | Mizuho Securities | BUY | $30.00 |
| 16 Mar 2026 | Barclays | BUY | $28.00 |
| 13 Mar 2026 | H.C. Wainwright | BUY | $27.00 |
No comments yet — be the first to weigh in on CRVS.
Sign in to join the discussion.